Anti-PD-1-anti-VEGF bispecific antibody, pharmaceutical composition and application thereof

By designing anti-PD-1-anti-VEGF bispecific antibodies, the problem of inability to block the binding of VEGFA to VEGFR2 and PD-1 and PD-L1 in the prior art is solved, and tumor angiogenesis and immunosuppression are achieved. effective inhibition has significant therapeutic potential.

CN119039450AInactive Publication Date: 2024-11-29SHANGHAI JUNSHI BIOSCIENCES CO LTD
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202310575606.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art has not yet developed a bifunctional antibody that can target PD-1 and VEGF simultaneously, blocking the binding of VEGFA to VEGFR2 and the binding of PD-1 to PD-L1, thereby effectively inhibiting tumor angiogenesis and immunosuppression.

Method used

Develop a bispecific antibody against PD-1-anti-VEGF, which contains anti-PD-1 and anti-VEGF antibody functional regions, and is able to bind VEGF and PD-1 at the same time and block VEGFA through specific amino acid sequence design. Binding to VEGFR2 and binding of PD-1 to PD-L1 activates immune responses and inhibits tumor angiogenesis.

Benefits of technology

This bispecific antibody can effectively bind VEGF and PD-1, block the corresponding signaling pathways, inhibit tumor angiogenesis and immunosuppression, and has the potential to prevent and treat malignant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039450A_ABST
    Figure CN119039450A_ABST
Patent Text Reader

Abstract

The present application provides bispecific antibodies that target PD-1 and VEGF and compositions comprising the same. Nucleic acid molecules encoding the bispecific antibodies of the application, vectors and host cells for expressing the bispecific antibodies of the application, and therapeutic and diagnostic methods and uses of the antibodies of the application or antigen binding fragments thereof are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the fields of tumor treatment and immunology biology, and in particular to an anti-PD-1-anti-VEGF bispecific antibody, a pharmaceutical composition thereof, and uses thereof. Background Art

[0002] Vascular endothelial growth factor (VEGF) is a type of growth factor that can promote endothelial cell division and proliferation, promote the formation of new blood vessels, and increase vascular permeability. It binds to the vascular endothelial growth factor receptor on the cell surface and exerts its function by activating the tyrosine kinase signal transduction pathway. In tumor tissues, tumor cells, tumor-invading macrophages and mast cells can secrete high levels of VEGF, which stimulate tumor vascular endothelial cells in the form of paracrine, promote endothelial cell proliferation and migration, induce angiogenesis, promote continuous tumor growth, and increase vascular permeability, causing fibrin deposition in surrounding tissues, promoting the infiltration of monocytes and fibroblasts into endothelial cells, facilitating the formation of tumor matrix and the entry of tumor cells into new blood vessels, promoting tumor metastasis, and thus inhibiting tumor angiogenesis is considered to be one of the most promising tumor treatment methods currently. The VEGF family includes: VEGFA, VEGFB, VEGFC, VEGFD and PIGF. VEGF family molecules have different affinities for several receptors. VEGFA mainly binds to VEGFR1, VEGFR2 and NRP-1 to exert its effects. Currently, there are many humanized monoclonal antibodies targeting human VEGF, especially VEGFA, such as Bevacizumab, which was approved by the US Food and Drug Administration in 2004 for the treatment of non-small cell lung cancer, renal cell carcinoma, cervical cancer, metastatic colorectal cancer and other tumors.

[0003] Programmed cell death protein (PD-1), also known as CD279, is a type I transmembrane glycoprotein membrane surface receptor that belongs to the CD28 immunoglobulin superfamily and is widely expressed in T cells, B cells, and myeloid cells. PD-1 has two natural ligands, PD-L1 and PD-L2. Both PD-L1 and PD-L2 belong to the B7 superfamily and are constitutively or inducibly expressed on the surface of a variety of cell membranes, including non-hematopoietic system cells and a variety of tumor cells. PD-L1 is mainly expressed in T cells, B cells, DCs, microvascular endothelial cells, and a variety of tumor cells. PD-L2 is only expressed in antigen-presenting cells such as dendritic cells and macrophages. The interaction between PD-1 and its ligands can inhibit lymphocyte activation, T cell proliferation, and the secretion of cytokines such as IL-2 and IFN-γ. Due to the broad-spectrum anti-tumor prospects and amazing efficacy of PD-1 antibodies, the industry generally believes that antibodies targeting the PD-1 pathway will bring breakthrough progress in the treatment of various tumors: for the treatment of non-small cell lung cancer, renal cell carcinoma, ovarian cancer, melanoma (Homet MB, Parisi G., et al., Anti-PD-1 Therapy in Melanoma. Semin Oncol. 2015 Jun; 42(3): 466-473), lymphoma and anemia (Held SA, Heine A, et al., Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets. 2013 Sep; 13(7): 768-74).

[0004] Bifunctional antibodies, also known as bispecific antibodies, are specific drugs that simultaneously target two different antigens. They can be produced by immunosorting and purification, or obtained through genetic engineering. Many bispecific antibodies that have been developed are in the form of IgG-ScFv, namely the Morrison model (1997Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. Nature Biotechnology, 1997; 15: 159-163). Due to its advantages in antibody engineering, expression and purification, this form is similar to the naturally occurring IgG form and has been proven to be an ideal form of bifunctional antibodies (Miller BR, Demarest SJ, et al., Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23: 549-57; Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 2011; 3: 299-309). Currently, there is still a need to develop a bifunctional antibody drug that simultaneously targets PD-1 and VEGF (such as VEGFA). Summary of the invention

[0005] The purpose of the present application is to provide an anti-PD-1-anti-VEGF bispecific antibody, a pharmaceutical composition thereof and a use thereof, wherein the bispecific antibody can simultaneously bind to VEGF and PD-1, block the binding of VEGFA to VEGFR2 and block the binding of PD-1 to PD-L1.

[0006] In a first aspect, the present application provides a bispecific antibody comprising a first protein functional region and a second protein functional region; wherein: the first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, and the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, and the anti-VEGF antibody or its antigen-binding fragment comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0007] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab.

[0008] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment comprises a heavy chain variable region and / or a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0009] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment comprises a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11; and / or the anti-VEGF antibody or its antigen-binding fragment comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 12.

[0010] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or, the anti-VEGF antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

[0011] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and / or the second protein functional region is a single domain antibody.

[0012] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

[0013] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the constant region of the immunoglobulin is from a human antibody; preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

[0014] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the second protein functional region is a single domain antibody; there are two single domain antibodies, and one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin; or one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or the N-terminus of each of the single domain antibodies is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each of the single domain antibodies is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

[0015] In some embodiments of the present application, the bispecific antibody is selected from the following forms: (1) the first polypeptide chain of the bispecific antibody is as shown in the formula VLPD-1-CL, and the second polypeptide chain is as shown in the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or (2) the first polypeptide chain of the bispecific antibody is as shown in the formula VLPD-1-CL, and the second polypeptide chain is as shown in the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or (3) the first polypeptide chain of the bispecific antibody is as shown in the formula VLPD-1-CL, and the second polypeptide chain is as shown in the formula VHPD-1-CH1-linker-VHVEGF-linker-hinge-CH2-CH3; or (4) the first polypeptide chain of the bispecific antibody is as shown in the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is as shown in the formula VHPD-1-CH1-hinge-CH2-CH3.

[0016] In some embodiments of the present application, the bispecific antibody is selected from the following: (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or (4) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 18.

[0017] The second aspect of the present application provides an isolated nucleic acid molecule encoding the bispecific antibody described in the first aspect of the present application.

[0018] The third aspect of the present application provides a vector comprising the isolated nucleic acid molecule described in the second aspect of the present application.

[0019] The fourth aspect of the present application provides a host cell, which comprises the isolated nucleic acid molecule described in the second aspect of the present application, or the vector described in the third aspect of the present application.

[0020] The fifth aspect of the present application provides a method for preparing the bispecific antibody described in the first aspect of the present application, which comprises the steps of culturing the host cell described in the fourth aspect of the present application, and obtaining the bispecific antibody from the culture.

[0021] The sixth aspect of the present application provides a conjugate, which comprises the bispecific antibody described in the first aspect of the present application and a conjugated portion, wherein the conjugated portion is a detectable label; preferably, the conjugated portion is selected from a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0022] The seventh aspect of the present application provides a kit, which comprises the bispecific antibody described in the first aspect of the present application, or comprises the conjugate described in the sixth aspect of the present application; preferably, the kit further comprises a second antibody, and the second antibody can specifically bind to the bispecific antibody; preferably, the second antibody further comprises a detectable label, and more preferably, the detectable label is selected from a radioactive isotope, a fluorescent substance, a colored substance or an enzyme.

[0023] The eighth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application in preparing a kit; preferably, the kit is used to detect the presence or level of VEGF and / or PD-1 in a sample.

[0024] The ninth aspect of the present application provides a pharmaceutical composition, which comprises the bispecific antibody described in the first aspect of the present application or the conjugate described in the sixth aspect of the present application; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

[0025] The tenth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of a drug for preventing and / or treating malignant tumors.

[0026] The eleventh aspect of the present application provides the use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents: a reagent for detecting the level of VEGF in a sample.

[0027] The twelfth aspect of the present application provides an in vitro method for non-diagnostic and non-therapeutic purposes, comprising the step of applying an effective amount of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application to cells, wherein the method is selected from the following:

[0028] (1) a method for detecting the level of VEGF in a sample, or a method for blocking the binding of VEGF to VEGFR, or a method for downregulating the activity or level of VEGF, or a method for relieving the stimulating effect of VEGF on the proliferation of vascular endothelial cells, or a method for inhibiting the proliferation of vascular endothelial cells, or a method for blocking tumor angiogenesis; and / or

[0029] (2) A method for blocking the binding of PD-1 to PD-L1, or a method for downregulating the activity or level of PD-1, or a method for relieving the immunosuppression of the body by PD-1, or a method for promoting the secretion of IFN-r in T lymphocytes, or a method for promoting the secretion of IL-2 in T lymphocytes.

[0030] Beneficial effects of this application:

[0031] The bispecific antibody provided in the present application can bind to VEGFA specifically and effectively, and can very effectively block the binding of VEGFA to VEGFR2, specifically relieving the immunosuppression of the body and the promoting effect of VEGFA on angiogenesis; it can bind to PD-1 specifically and effectively, and can very effectively block the binding of PD-1 to PD-L1, specifically relieving the immunosuppression of the body by PD-1 and activating the immune response.

[0032] Of course, implementing any product or method of the present application does not necessarily require achieving all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application, and for ordinary technicians in this field, other embodiments can also be obtained based on these drawings.

[0034] Figure 1 is a schematic diagram of the structure of DotAb4;

[0035] Figure 2a is a schematic diagram of the structure of antibody 23;

[0036] Figure 2b is a schematic diagram of the structure of antibody 24;

[0037] Figure 2c is a schematic diagram of the structure of antibody 27;

[0038] Figure 2d is a schematic diagram of the structure of antibody 28;

[0039] Figure 3a This is the binding and dissociation curve diagram of antibody JS001 and human PD-1;

[0040] Figure 3b It is the binding and dissociation curve diagram of antibody 23 and human PD-1;

[0041] Figure 3c It is the binding and dissociation curve diagram of antibody 24 and human PD-1;

[0042] Figure 3d It is the binding and dissociation curve diagram of antibody 27 and human PD-1;

[0043] Figure 3e It is the binding and dissociation curve diagram of antibody 28 and human PD-1;

[0044] Figure 4a It is the binding and dissociation curve diagram of antibody DotAb4 and human VEGFA;

[0045] Figure 4b is the binding and dissociation curve diagram of antibody 23 and human VEGFA;

[0046] Figure 4c is the binding and dissociation curve diagram of antibody 24 and human VEGFA;

[0047] Figure 4d is the binding and dissociation curve diagram of antibody 27 and human VEGFA;

[0048] Figure 4e is the binding and dissociation curve diagram of antibody 28 and human VEGFA;

[0049] Figure 5a This is the result graph of the test sample group antibody 27 binding to two antigens, human PD-1 and human VEGFA;

[0050] Figure 5b This is the non-specific binding result diagram of human VEGFA and human PD-1 in the negative control group;

[0051] Figure 5c This is the non-specific binding result diagram of human VEGFA and JS001 in the negative control group;

[0052] Figure 6a ELISA curves of the binding of antibody 23 and antibody 24 to human PD-1;

[0053] Figure 6b ELISA curves of the binding of antibody 27 and antibody 28 to human PD-1;

[0054] Figure 7a ELISA curves of the binding of antibody 23, antibody 24 and human VEGFA;

[0055] Figure 7b ELISA curves of the binding of antibody 27, antibody 28 and human VEGFA;

[0056] Figure 8a It is the competitive inhibition ELISA curve diagram of antibody 23 and antibody 24 blocking human VEGFR2 and VEGFA;

[0057] Figure 8bIt is the competitive inhibition ELISA curve diagram of antibody 27 and antibody 28 blocking human VEGFR2 and VEGFA;

[0058] Figure 9a This is the competitive inhibition ELISA curve of antibody 23 and antibody 24 blocking human PD-L1 and PD-1;

[0059] Figure 9b This is the competitive inhibition ELISA curve of antibody 27 and antibody 28 blocking human PD-L1 and PD-1;

[0060] Fig.10a This is a graph showing the activity test results of antibody 23 and antibody 24 in the PD-1 / PD-L1 luciferase reporter gene system;

[0061] Fig.10b This is a graph showing the activity test results of antibody 27 and antibody 28 in the PD-1 / PD-L1 luciferase reporter gene system;

[0062] Fig.11a The figure shows the activity detection results of the luciferase reporter gene system in which antibodies 23 and 24 blocked VEGF-induced NFAT signaling;

[0063] Fig.11b The figure shows the activity detection results of antibody 27 and antibody 28 blocking VEGF-induced NFAT signal in the luciferase reporter gene system;

[0064] Fig.12a The figure shows the experimental results of antibody 23 and antibody 24 inhibiting VEGFA-induced HUVEC cell proliferation;

[0065] Figure 12b The figure shows the experimental results of antibody 27 and antibody 28 inhibiting the proliferation of HUVEC cells induced by VEGFA;

[0066] Fig.13a The figure is the experimental result that the antibody promotes the secretion of cytokine IL2 in the mixed lymphocyte reaction of donor 1;

[0067] Fig.13b The figure is the experimental result that the antibody promotes the secretion of cytokine IL2 in the mixed lymphocyte reaction of donor 2;

[0068] Fig.13c The figure is the experimental result that the antibody promotes the secretion of cytokine IFN-γ in the mixed lymphocyte reaction of donor 1;

[0069] Fig.13d The figure is the experimental result that the antibody promotes the secretion of cytokine IFN-γ in the mixed lymphocyte reaction of donor 2;

[0070] Fig.14 This is a graph showing the inhibitory effect of the test substance on the MC38 tumor model transplanted into B-PD-1 humanized mice. DETAILED DESCRIPTION

[0071] The present application is illustrated by the following examples, but is not intended to limit the present application in any way. The present application has been described in detail herein, and its specific embodiments are also disclosed. It will be apparent to those skilled in the art that various changes and modifications will be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0072] In this application, unless otherwise specified, the scientific and technical terms used in this application have the meanings commonly understood by those skilled in the art. In addition, the cell culture, molecular genetics, nucleic acid chemistry, and immunology laboratory operation steps used in this application are all conventional steps widely used in the corresponding fields. At the same time, in order to better understand this application, the definitions and explanations of relevant terms are provided below.

[0073] As used in this application, when referring to the amino acid sequence of VEGFA protein (GenBank ID: NP_001165097.1), it includes the full length of VEGFA protein, and also includes fusion proteins of VEGFA, such as fragments fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) may be naturally produced or artificially introduced into the amino acid sequence of VEGFA protein without affecting its biological function. Therefore, in this application, the term "VEGFA protein" shall include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of VEGFA protein, it also includes the corresponding sequence fragments in its natural or artificial variants. In one embodiment of the present application, the amino acid sequence of the VEGFA protein is as shown in SEQ ID NO: 19 (excluding the terminal His, the VEGFA protein used in the examples of the present application was purchased from ARCO, name: Human VEGF165 Protein, HisTag, product number: VE5-H5248, batch number: 2410-2069F1-146).

[0074] As used in this application, when referring to the amino acid sequence of VEGFR2 protein (KDR) (GenBank ID: NP_002244), it includes the full length of VEGFR2 protein, or the extracellular fragment VEGFR2-ECD of VEGFR2 or a fragment comprising VEGFR2-ECD; it also includes a fusion protein of VEGFR2-ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) may be naturally generated or artificially introduced into the amino acid sequence of VEGFR2 protein without affecting its biological function. Therefore, in the present application, the term "VEGFR2 protein" shall include all such sequences, including their natural or artificial variants. Moreover, when describing a sequence fragment of the VEGFR2 protein, it also includes the corresponding sequence fragments in its natural or artificial variants. In one embodiment of the present application, the amino acid sequence of VEGFR2 is shown in SEQ ID NO: 20 (the VEGFR2 protein used in the examples of the present application was purchased from Sino Biological, name: VEGFR2 / KDR Protein, Human, Recombinant (His Tag), Biotinylated, Cat: 10012-H08H-B).

[0075] As used in this application, unless otherwise specified, the VEGFR is VEGFR1 and / or VEGFR2; its specific protein sequence is a known sequence in the prior art, and can refer to the sequence disclosed in existing literature or GenBank. For example, VEGFR1 (VEGFR1, NCBI Gene ID: 2321); VEGFR2 (VEGFR2, NCBI Gene ID: 3791).

[0076] As used in this application, when referring to the amino acid sequence of PD-1 protein (Programmed cell death protein 1, NCBI GenBank: NM_005018), it includes the full length of PD-1 protein, or the extracellular fragment PD-1ECD of PD-1 or a fragment containing PD-1ECD; it also includes a fusion protein of PD-1ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that in the amino acid sequence of PD-1 protein, mutations or variations (including but not limited to substitutions, deletions and / or additions) may be naturally generated or artificially introduced without affecting its biological function. Therefore, in this application, the term "PD-1 protein" shall include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of PD-1 protein, it also includes the corresponding sequence fragment in its natural or artificial variant.

[0077] As used in this application, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.

[0078] As used in this application, the term "antibody" refers to an immunoglobulin molecule that is usually composed of two pairs of polypeptide chains (each pair has a "light" (L) chain and a "heavy" (H) chain). In a general sense, the heavy chain can be understood as the polypeptide chain with a larger molecular weight in the antibody, and the light chain refers to the polypeptide chain with a smaller molecular weight in the antibody. Light chains can be classified as κ and λ light chains. Heavy chains can usually be classified as μ, δ, γ, α or ε, and the isotype of the antibody is defined as IgM, IgD, IgG, IgA and IgE, respectively. Within the light chain and heavy chain, the variable region and the constant region are connected by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of 3 domains (CH1, CH2 and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be subdivided into regions with high variability, called complementary determining regions (CDRs), interspersed with more conservative regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antibody binding site, respectively. The allocation of amino acids to each region or domain follows the definition of Kabat Sequences of Proteins of Immunological Interest Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883. In particular, the heavy chain can also contain more than 3 CDRs, such as 6, 9, or 12. For example, in the bifunctional antibody of the present application, the heavy chain can be the C-terminus of the heavy chain of an IgG antibody connected to the ScFv of another antibody, in which case the heavy chain contains 9 CDRs. The term "antibody" is not limited to any particular method for producing antibodies. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibodies can be of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3, or IgG4 subtype), IgA1, IgA2, IgD, IgE, or IgM antibodies.

[0079] As used in this application, the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to the same antigen to which the full-length antibody binds, and / or competes with the full-length antibody for specific binding to the antigen, which is also referred to as an "antigen-binding portion". See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd edition, Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact antibodies. In some cases, antigen-binding fragments include Fab, Fab', F(ab')2, Fd, Fv, single-domain antibodies (sdAb) and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and polypeptides that contain at least a portion of an antibody sufficient to confer specific antigen-binding ability to a polypeptide.

[0080] As used in this application, the term "Fd fragment" means an antibody fragment consisting of VH and CH1 domains; the term "Fv fragment" means an antibody fragment consisting of the VL and VH domains of a single arm of an antibody; the term "dAb fragment" means an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of VL, VH, CL and CH1 domains; the term "F(ab')2 fragment" means an antibody fragment comprising two Fab fragments connected by a disulfide bridge on the hinge region.

[0081] In some cases, the antigen-binding fragment of an antibody is a single-chain antibody (e.g., scFv), in which the VL and VH domains are paired to form a monovalent molecule by a linker that enables them to be produced as a single polypeptide chain (see, e.g., Bird et al., Science 242: 423-426 (1988) and Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988)). Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having an amino acid sequence (GGGGS) 4 may be used, but variants thereof may also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers that can be used in the present application are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.

[0082] In some cases, the antigen-binding fragment of an antibody is a diabody, i.e., a bivalent antibody in which the VH and VL domains are expressed on a single polypeptide chain, but with a linker that is too short to allow pairing between the two domains on the same chain, thereby forcing the domains to pair with the complementary domains of another chain and create two antigen-binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).

[0083] Antibody antigen-binding fragments (e.g., those described above) can be obtained from a given antibody using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods) and screened for specificity in the same manner as for intact antibodies.

[0084] In the present application, unless the context clearly indicates otherwise, when referring to the term "antibody", it includes not only intact antibodies but also antigen-binding fragments of antibodies.

[0085] As used in this application, the term "single-domain antibody" (sdAb), also known as "nanobody", has the meaning generally understood by those skilled in the art, and refers to an antibody fragment composed of a single monomeric variable antibody domain (e.g., a single heavy chain variable region), usually derived from the variable region of a heavy chain antibody (e.g., a camelid antibody or a shark antibody). Typically, a nanobody consists of four framework regions and three complementarity determining regions, and has a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Nanobodies can be truncated at the N-terminus or C-terminus so that they only contain part of FR1 and / or FR4, or lack one or two of those framework regions, as long as they substantially maintain antigen binding and specificity. DotAb4 is a heavy chain antibody connected to Fc on a single domain antibody. DotAb4 can contain two identical polypeptide chains, and the structure of each polypeptide chain is shown in the formula DotAb-hinge-CH2-CH3, and its structural schematic diagram is shown in Figure 1 shown.

[0086] As used in this application, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or a fragment of an antibody from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for natural mutations that may occur spontaneously. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies, and they usually contain at least two or more different antibodies, and these different antibodies usually recognize different epitopes on the antigen. Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. (Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (see, for example, USP 4,816,567).

[0087] As used in the present application, the term "chimeric antibody" refers to an antibody in which a portion of its light chain and / or heavy chain is derived from one antibody (which may be derived from a particular species or belong to a particular antibody class or subclass), and another portion of the light chain and / or heavy chain is derived from another antibody (which may be derived from the same or different species or belong to the same or different antibody class or subclass), but in any case, it still retains binding activity to the target antigen (USP 4,816,567 to Cabilly et al.; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851 6855 (1984)).

[0088] As used in this application, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat or rabbit) antibody with the desired specificity, affinity or reactivity. In addition, some amino acid residues in the framework region (FR) of the receptor antibody can also be replaced by amino acid residues of the corresponding non-human antibody, or by amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature, 321: 522 525 (1986); Reichmann et al., Nature, 332: 323 329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593 596 (1992); and Clark, Immunol. Today 21: 397 402 (2000).

[0089] As used in the present application, the term "epitope" refers to the site on an antigen that is specifically bound by an immunoglobulin or antibody. "Epitope" is also referred to as "antigenic determinant" in the art. An epitope or antigenic determinant is usually composed of chemically active surface groups of a molecule such as amino acids or carbohydrates or sugar side chains and usually has specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope usually includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 continuous or non-continuous amino acids in a unique spatial conformation, which can be "linear" or "conformational". See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). In a linear epitope, all interacting points between a protein and an interacting molecule (e.g., an antibody) exist linearly along the primary amino acid sequence of the protein. In a conformational epitope, the interacting points exist across separate protein amino acid residues.

[0090] As used in this application, the term "isolated" or "separated" refers to that obtained from the natural state by artificial means. If a certain "isolated" substance or component appears in nature, it may be that the natural environment in which it is located has changed, or the substance has been separated from the natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity separated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.

[0091] As used in this application, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, and include but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses, etc. Animal viruses that can be used as vectors include but are not limited to retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses (such as SV40). A vector can contain a variety of elements that control expression, including but not limited to promoter sequences, transcription initiation sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication initiation site.

[0092] As used in this application, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.

[0093] As used in this application, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and an antigen to which it is directed. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10-8 M, 10 -9 M or 10 -10 M or less affinity (KD) binds to the antigen. In some embodiments of the present application, the term "targeting" refers to specific binding.

[0094] As used in this application, the term "KD" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies bind to the antigen with a KD of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The antigen is bound to the antigen with a dissociation equilibrium constant (KD) of M or less, e.g., as determined using surface plasmon resonance (SPR) in a BIACORE instrument.

[0095] As used in this application, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. And in this application, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0096] As used in this application, the term "pharmaceutically acceptable excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with a subject and an active ingredient, which is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH regulators, surfactants, adjuvants, and ionic strength enhancers. For example, pH regulators include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80; ionic strength enhancers include, but are not limited to, sodium chloride.

[0097] As used in this application, the term "adjuvant" refers to a non-specific immunopotentiator, which, when delivered into the body together with an antigen or in advance, can enhance the body's immune response to the antigen or change the immune response type. There are many kinds of adjuvants, including but not limited to aluminum adjuvants (such as aluminum hydroxide), Freund's adjuvants (such as complete Freund's adjuvant and incomplete Freund's adjuvant), Corynebacterium brevis, lipopolysaccharide, cytokines, etc. Freund's adjuvant is the most commonly used adjuvant in current animal experiments. Aluminum hydroxide adjuvant is used more in clinical trials.

[0098] As used in this application, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a disease related to the binding of PD-1 to PD-L1 or excessive expression of VEGF, such as a tumor) refers to an amount sufficient to prevent, prevent, or delay the occurrence of a disease (e.g., a disease related to the binding of PD-1 to PD-L1 or excessive expression of VEGF, such as a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and gender, the mode of administration of the drug, and other treatments administered simultaneously.

[0099] After in-depth research and creative work, the inventors of the present application have obtained a humanized bispecific antibody that can simultaneously bind to VEGF and PD-1, and can simultaneously block the binding of VEGFA to VEGFR2, and block the binding of PD-1 to PD-L1.

[0100] The inventors of the present application have discovered that the bispecific antibodies described in the present application can: effectively bind to PD-1 on the surface of human immune cells, relieve PD-L1 and PD-1-mediated immunosuppression, and promote the secretion of IFN-γ and IL-2 by human immune cells; effectively inhibit VEGFA-induced proliferation of vascular endothelial cells, thereby inhibiting tumor-induced angiogenesis; and / or have the potential to be used in the preparation of drugs for the prevention and treatment of malignant tumors.

[0101] In a first aspect, the present application provides a bispecific antibody comprising a first protein functional region and a second protein functional region; wherein: the first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, and the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, and the anti-VEGF antibody or its antigen-binding fragment comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0102] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region; the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab.

[0103] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment comprises a heavy chain variable region and / or a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 with amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

[0104] In some embodiments of the present application, the anti-PD-1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11; and / or

[0105] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO: 12.

[0106] The variable regions of the light and heavy chains determine the binding of antigens; the variable region of each chain contains three hypervariable regions, called complementarity determining regions (CDRs). The CDRs of the heavy chain (H) include HCDR1, HCDR2, and HCDR3, and the CDRs of the light chain (L) include LCDR1, LCDR2, and LCDR3; they were named by Kabat et al., see Sequences of Proteins of Immunological Interest, Fifth Edition (1991), Volumes 1-3, NIH Publication 91-3242, Bethesda Md).

[0107] Methods and techniques for identifying CDRs in the amino acid sequences of heavy chain variable regions and light chain variable regions are known in the art and can be used to identify CDRs in the amino acid sequences of specific heavy chain variable regions and / or light chain variable regions disclosed herein. Exemplary well-known techniques that can be used to identify CDR boundaries include, for example, Kabat definition, Chothia definition, and AbM definition. See, for example, Kabat, Sequences of Proteins of Immunological Interest, Bethesda, Md. (1991); Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins., J. Mol. Biol. 273:927-948 (1997); and Martin AC et al., Modeling antibody hypervariable loops: a combined algorithm, Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989).

[0108] The amino acid sequence of the CDR region of the bispecific antibody described in the present application was obtained by means of techniques well known to those skilled in the art (KABAT scheme), and the specific sequence is as follows:

[0109] The anti-PD-1 antibody or its antigen-binding fragment contains three heavy chain complementary determining regions:

[0110] PD-1-HCDR1:DYEMH (SEQ ID NO: 1);

[0111] PD-1-HCDR2: VIESETGGTAYNQKFKG (SEQ ID NO: 2);

[0112] PD-1-HCDR3: EGITTVATTYYWYFDV (SEQ ID NO: 3).

[0113] The anti-PD-1 antibody or its antigen-binding fragment contains three light chain complementary determining regions:

[0114] PD-1-LCDR1: RSSQSIVHSNGNTYLE (SEQ ID NO: 4);

[0115] PD-1-LCDR2: KVSNRFS (SEQ ID NO: 5);

[0116] PD-1-LCDR3: FQGSHVPLT (SEQ ID NO: 6).

[0117] The anti-VEGF antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions:

[0118] VEGF-HCDR1: ATDID (SEQ ID NO: 7);

[0119] VEGF-HCDR2: RIFSPSDFTDYADSVKG (SEQ ID NO: 8);

[0120] VEGF-HCDR3: PDTYAYNIFLDTPTYNALHY (SEQ ID NO: 9).

[0121] In some embodiments of the present application, the bispecific antibody, wherein,

[0122] The anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 10 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 11; and / or

[0123] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:12.

[0124] The heavy chain variable region (VH) comprised by an anti-PD-1 antibody or an antigen-binding fragment thereof, wherein the bold underlined portion represents the CDR:

[0125] PD-1-VH:

[0126] The light chain variable region (VL) comprised by an anti-PD-1 antibody or an antigen-binding fragment thereof, wherein the bold underlined portion represents the CDR:

[0127] PD-1-VL:

[0128] The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH), wherein the bold underlined portion represents the CDR:

[0129] VEGF-VH:

[0130] In some embodiments of the present application, the anti-PD-1 antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or, the anti-VEGF antibody or its antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

[0131] In some embodiments of the present application, the first protein functional region is an immunoglobulin, whose heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and its light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and / or, the second protein functional region is a single domain antibody, whose heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

[0132] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

[0133] In some embodiments of the present application, the first protein functional region is an immunoglobulin, which includes a non-CDR region, and the non-CDR region is from a species other than a mouse, such as a human antibody.

[0134] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the constant region of the immunoglobulin is from a human antibody; preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

[0135] In some embodiments of the present application, the first protein functional region is an immunoglobulin, and the second protein functional region is a single domain antibody; there are two single domain antibodies, and one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin; or one end of each of the single domain antibodies is respectively connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or the N-terminus of each of the single domain antibodies is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each of the single domain antibodies is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

[0136] In some embodiments of the present application, the bispecific antibody is selected from the following forms:

[0137] (1) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or

[0138] (2) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or

[0139] (3) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-linker-VHVEGF-linker-hinge-CH2-CH3; or

[0140] (4) The first polypeptide chain of the bispecific antibody is represented by the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3.

[0141] The VLPD-1 described in the present application refers to the VL of an anti-PD-1 antibody or an antigen-binding fragment thereof, VHPD-1 refers to the VH of an anti-PD-1 antibody or an antigen-binding fragment thereof, and VHVEGF refers to the VH of an anti-VEGF antibody or an antigen-binding fragment thereof.

[0142] The present application has no particular limitation on the amino acid sequence of the linker, as long as the purpose of the invention of the present application can be achieved. For example, the amino acid sequence of the linker can be (GGGGS)n, wherein n is selected from 1, 2, 3, 4 or 5, preferably 1, 2 or 3. The present application has no particular limitation on the amino acid sequence of the hinge, as long as the purpose of the invention of the present application can be achieved.

[0143] In some embodiments of the present application, the bispecific antibody is selected from the following:

[0144] (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or

[0145] (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or

[0146] (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or

[0147] (4) The first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 18.

[0148] The specific sequence is as follows:

[0149] DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIY

[0150] KVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEI

[0151] KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES

[0152] VTEQDSKDSTYSLSSTLLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO: 13);

[0153] (SEQ ID NO: 14);

[0154] (SEQ ID NO: 15);

[0155] (SEQ ID NO: 16);

[0156] EVQLVESGGGLVQPGGSLRLSCAISGFSLAATDIDWVRQAPGKGLEWVARIFSPSDFTDYADSVKGRFTISADTSKNTVYLQMNSLRAEDTAVYYCGRPDTYAYNIFLDTPTYNALHYRGQGTLVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLE WYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIKRTVAAPSVFIFPPSDEQSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO: 17);

[0157] QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDV WGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG PPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO: 18).

[0158] The second aspect of the present application provides an isolated nucleic acid molecule encoding the bispecific antibody described in the first aspect of the present application.

[0159] The third aspect of the present application provides a vector comprising the isolated nucleic acid molecule described in the second aspect of the present application.

[0160] The fourth aspect of the present application provides a host cell, which comprises the isolated nucleic acid molecule described in the second aspect of the present application, or comprises the vector described in the third aspect of the present application.

[0161] The fifth aspect of the present application provides a method for preparing the bispecific antibody described in the first aspect of the present application, which comprises culturing the host cell described in the fourth aspect of the present application under suitable conditions, and recovering the bispecific antibody from the cell culture.

[0162] The sixth aspect of the present application provides a conjugate, which comprises the bispecific antibody described in the first aspect of the present application and a conjugated portion, wherein the conjugated portion is a detectable label; preferably, the conjugated portion is selected from a radioactive isotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0163] The seventh aspect of the present application provides a kit, which comprises the bispecific antibody described in the first aspect of the present application, or comprises the conjugate described in the sixth aspect of the present application.

[0164] Preferably, the kit further comprises a second antibody that is capable of specifically binding to the bispecific antibody; optionally, the second antibody further comprises a detectable label, such as a radioisotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

[0165] The eighth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application in preparing a kit; preferably, the kit is used to detect the presence or level of VEGF and / or PD-1 in a sample.

[0166] The ninth aspect of the present application provides a pharmaceutical composition, which comprises the bispecific antibody described in the first aspect of the present application or the conjugate described in the sixth aspect of the present application; optionally, it also includes a pharmaceutically acceptable excipient.

[0167] The bispecific antibody provided in the first aspect of the present application or the pharmaceutical composition provided in the ninth aspect of the present application can be configured into any dosage form known in the pharmaceutical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended mode of administration and therapeutic use. The pharmaceutical composition of the present application should be sterile and stable under production and storage conditions, and the preferred dosage form is an injection. Such injections can be sterile injection solutions. For example, a sterile injection solution can be prepared by the following method: a necessary dose of the bispecific antibody of the present application is added to an appropriate solvent, and optionally, other desired ingredients (including but not limited to pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof) are added at the same time, followed by filtration and sterilization. In addition, a sterile injection solution can be prepared as a sterile lyophilized powder (e.g., by vacuum drying or freeze drying) for easy storage and use. Such sterile lyophilized powders can be dispersed in a suitable carrier, such as water for injection, before use.

[0168] In addition, the bispecific antibody of the present application can be present in a pharmaceutical composition in a unit dosage form, so as to facilitate administration. In certain embodiments, the unit dosage is at least 1mg, at least 5mg, at least 10mg, at least 15mg, at least 25mg, at least 30mg, at least 45mg, at least 50mg, at least 75mg, or at least 100mg. In the case where the pharmaceutical composition is a liquid (e.g., injection) dosage form, it can include a concentration of at least 0.1mg / mL, such as at least 0.25mg / mL, at least 0.5mg / mL, at least 1mg / mL, at least 2.5mg / mL, at least 5mg / mL, at least 8mg / mL, at least 10mg / mL, at least 15mg / mL, at least 25mg / mL, at least 50mg / mL, at least 75mg / mL, or at least 100mg / mL of the bispecific antibody of the present application.

[0169] The bispecific antibody or pharmaceutical composition of the present application can be applied by any suitable method known in the art, including but not limited to oral, oral, sublingual, eyeball, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (such as, powder, ointment or drops), or nasal route. However, for many therapeutic uses, preferred route of administration / mode is parenteral administration (such as intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Technicians should understand that route of administration and / or mode will change according to the intended purpose. In a preferred embodiment, the bispecific antibody or pharmaceutical composition of the present application are given by intravenous infusion or injection.

[0170] The bispecific antibody or pharmaceutical composition provided in the present application can be used alone or in combination, or can be used in combination with another pharmaceutically active agent (e.g., a tumor chemotherapy drug). Such another pharmaceutically active agent can be administered before, simultaneously, or after the administration of the bispecific antibody or pharmaceutical composition of the present application.

[0171] In the present application, the dosage regimen can be adjusted to obtain the best intended response (e.g., treatment or prevention response). For example, a single dose can be administered, multiple doses can be administered over a period of time, or the dosage can be proportionally reduced or increased according to the urgency of the treatment situation.

[0172] The tenth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of a drug for preventing and / or treating malignant tumors.

[0173] The eleventh aspect of the present application provides the use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents: a reagent for detecting the level of VEGF in a sample.

[0174] The twelfth aspect of the present application provides use of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application in the preparation of the following drugs or reagents:

[0175] (1) a drug or agent for detecting the level of VEGFA in a sample, or a drug or agent for blocking the binding of VEGFA to VEGFR2, or a drug or agent for downregulating the activity or level of VEGFA, or a drug or agent for relieving the stimulatory effect of VEGFA on the proliferation of vascular endothelial cells, or a drug or agent for inhibiting the proliferation of vascular endothelial cells, or a drug or agent for blocking tumor angiogenesis; and / or

[0176] (2) Drugs or agents that block the binding of PD-1 to PD-L1, or drugs or agents that downregulate the activity or level of PD-1, or drugs or agents that relieve the immune suppression of the body by PD-1, or drugs or agents that promote the secretion of IFN-γ in T lymphocytes, or drugs or agents that promote the secretion of IL-2 in T lymphocytes.

[0177] In some embodiments of the present application, the use is for non-therapeutic and / or non-diagnostic purposes.

[0178] The thirteenth aspect of the present application provides an in vivo or in vitro method, comprising the step of applying an effective amount of the bispecific antibody described in the first aspect of the present application, the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application to cells, wherein the method is selected from the following:

[0179] (1) a method for detecting the level of VEGFA in a sample, or a method for blocking the binding of VEGFA to VEGFR2, or a method for downregulating the activity or level of VEGFA, or a method for relieving the stimulatory effect of VEGFA on vascular endothelial cell proliferation, or a method for inhibiting vascular endothelial cell proliferation, or a method for blocking tumor angiogenesis; and / or

[0180] (2) A method for blocking the binding of PD-1 to PD-L1, or a method for downregulating the activity or level of PD-1, or a method for relieving the immunosuppression of the body by PD-1, or a method for promoting the secretion of IFN-γ in T lymphocytes, or a method for promoting the secretion of IL-2 in T lymphocytes.

[0181] In some embodiments of the present application, the in vitro method is for non-therapeutic and / or non-diagnostic purposes.

[0182] In the in vitro experiments of the present application, the anti-VEGF-anti-PD-1 bispecific antibodies can specifically bind to the VEGF antigen, thereby inhibiting the proliferation of HUVEC cells; and the anti-VEGFA-anti-PD-1 bispecific antibodies can promote the secretion of IFNγ and / or IL-2, activating the immune response.

[0183] The fourteenth aspect of the present application provides a method for preventing and / or treating malignant tumors, comprising the step of administering to a subject an effective amount of the bispecific antibody described in the first aspect of the present application, or the conjugate described in the sixth aspect of the present application, or the pharmaceutical composition described in the ninth aspect of the present application.

[0184] The typical non-limiting range of the therapeutic or prophylactic effective amount of the bispecific antibody of the present application is 0.02-50 mg / kg. It should be noted that the dosage may vary depending on the type and severity of the symptoms to be treated. In addition, those skilled in the art understand that for any particular patient, the specific dosing regimen should be adjusted over time according to the patient's needs and the doctor's professional evaluation; the dosage range given here is only for illustrative purposes and does not limit the use or scope of the pharmaceutical composition of the present application.

[0185] In the present application, the subject may be a mammal, such as a human.

[0186] In the fifteenth aspect, the present application provides a bispecific antibody as described in the first aspect of the present application, or the conjugate as described in the sixth aspect of the present application, or the pharmaceutical composition as described in the ninth aspect of the present application, which is used for preventing and / or treating malignant tumors.

[0187] In a sixteenth aspect, the present application provides a bispecific antibody as described in the first aspect of the present application, or the conjugate as described in the sixth aspect of the present application, or the pharmaceutical composition as described in the ninth aspect of the present application, which is used for:

[0188] (1) detecting the level of VEGFA in a sample, or blocking the binding of VEGFA to VEGFR2, or downregulating the activity or level of VEGFA, or relieving the stimulatory effect of VEGFA on vascular endothelial cell proliferation, or inhibiting vascular endothelial cell proliferation, or blocking tumor angiogenesis; and / or

[0189] (2) Block the binding of PD-1 to PD-L1, or downregulate the activity or level of PD-1, or relieve the immune suppression of PD-1, or promote the secretion of IFN-γ in T lymphocytes, or promote the secretion of IL-2 in T lymphocytes.

[0190] The present application will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The reagents used in the experiment, if not otherwise specified, can all be commercially available. In addition, as long as there is no special explanation, "part" and "%" are mass references.

[0191] Example 1. Preparation of bispecific antibody molecules

[0192] 1. Construction of bispecific antibody molecule expression vector

[0193] (1) Construction of an expression vector for anti-PD-1 antibodies

[0194] The first expression vector corresponding to the light chain of the anti-PD-1 antibody: synthesize the DNA sequence encoding 3E4L1 (the specific sequence is shown in SEQ ID NO: 21), digest it with BSPQI and connect it to the HXT2 vector (the specific sequence is shown in SEQ ID NO: 22) to obtain the expression vector HXT2-3E4L1;

[0195] The second expression vector corresponding to the heavy chain of the anti-PD-1 antibody: The DNA sequence encoding 1A6H2-QGQ (the specific sequence is shown in SEQ ID NO: 23) was synthesized, cut with BSPQI and connected to the HXT4S vector (the specific sequence is shown in SEQ ID NO: 24) to obtain the expression vector HXT4S-1A6H2-QGQ.

[0196] (2) Construction of expression vector for anti-VEGF single domain antibody

[0197] A DNA sequence encoding IgG4-FC (specific sequence is shown in SEQ ID NO: 25) was synthesized, digested with BSPQI-NotI and ligated into the HXT4S vector to obtain the expression vector HX4-FC;

[0198] A DNA sequence encoding 16C2-1 (specific sequence as shown in SEQ ID NO: 26) was synthesized and inserted into the HX4-FC vector (specific sequence as shown in SEQ ID NO: 27) through the SapI-SapI site to obtain the expression vector HX4-16C2-1Fc.

[0199] (3) Construction of bispecific antibody molecule expression vector

[0200] 1) Bispecific antibody molecule 23:

[0201] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0202] The DNA sequence encoding 16C2-1-JS001 HC (specific sequence as shown in SEQ ID NO: 28) was synthesized, digested with EcoRI-NheI and ligated into the HXT4S vector to obtain the second expression vector HXT4S-16C2-1-JS001HC.

[0203] 2) Bispecific antibody molecule 24:

[0204] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0205] A DNA sequence encoding IgG4-16C2-1 (the specific sequence is shown in SEQ ID NO: 29) was synthesized, digested with NheI-NotI and ligated to the HXT4S-1A6H2-QGQ vector (i.e., the second expression vector corresponding to the heavy chain of the anti-PD-1 antibody) to obtain the second expression vector HXT4s-JS001 HC-16C2-1.

[0206] 3) Bispecific antibody molecule 27:

[0207] The construction method of the first expression vector HXT2-3E4L1 is the same as the construction method of the first expression vector in “(1) Construction of an expression vector for an anti-PD-1 antibody”;

[0208] The DNA sequence encoding JS001 HC-CH1-16C2-1 (specific sequence as shown in SEQ ID NO: 30) was synthesized, digested by SapI-SapI and ligated into the HX4-FC vector to obtain the second expression vector HXT4S-JS001HC-CH1-16C2-1-FC.

[0209] 4) Bispecific antibody molecule 28:

[0210] The DNA sequence encoding 16C2-1-3E4L1 was synthesized, digested with SapI-SapI and ligated into the HXT2 vector to obtain the first expression vector HXT2-16C2-1-3E4L1;

[0211] The construction method of the second expression vector HXT4S-1A6H2-QGQ is the same as the construction method of the second expression vector in “1. The second expression vector corresponding to the heavy chain of the anti-PD-1 antibody”.

[0212] 2. Expression of bispecific antibody molecules

[0213] Count the CHO-K1 cells in culture. When the cell density is between 2 and 6*10 6 / mL, use CD CHO (Thermofisher, 12490-003) medium for subculture and amplification. Dilute the cell density to 1.5-2.0*10 one day before transfection. 6 / mL, the next day when the cell density reaches about 3.0-4.0*10 6 / mL for transfection. First add one-tenth of the transfection volume of CDCHO culture medium, then add 1-2μg / mL of the plasmid (prepared in "1. Construction of bispecific antibody molecule expression vector" above), and finally add 3-14μg / mL of PEI (polyethyleneimine, Polysciences, 24765-1), mix well and incubate at room temperature for no more than 30 minutes, and finally slowly add the transfection mixture to the pre-treated CHO-K1 cells while mixing. The transfected mixture was cultured in a carbon dioxide shaker at 36.5°C, 110rpm, and 7% (volume fraction) CO2. On the first day after transfection, 4vol% Cell Boost 7a (Hyclone, SH31026.05) and 0.4vol% CellBoost 7b (Hyclone, SH31027.04CN) were fed, and then fed once every two days, and samples were collected 5-9 days after transfection.

[0214] 3. Purification of bispecific antibody molecules

[0215] After the culture was completed, the precipitate was discarded after centrifugation at 1000g for 5min, and then centrifuged at 12000g for 30min, the cell supernatant was collected and sterile filtered with a 0.22μm filter cup. Purification was performed using an AKTA Avant purifier. First, 0.1M NaOH was used to perform CIP on the mabselect sure LX column (Cytiva, 17547405) for 15-20min, and then the sample was loaded after balancing with PBS buffer until each curve became horizontal. After loading, the affinity chromatography elution buffer was used for elution, and finally the target protein was eluted with acetic acid-sodium acetate buffer at pH 3.6. The sample was neutralized with 1M Tris buffer, the pH was adjusted to 5.5, and the sample was sent to SEC-HPLC (molecular exclusion high performance liquid chromatography) to detect the purity of the sample. The remaining samples were purified in the next step; Eshmuno CPX (Merck, 1200830100) was used for purification, the equilibrium solution was pH 5.5 50mM acetic acid-sodium acetate system, the eluent was pH 5.5 50mM acetic acid-sodium acetate + 1M NaCl buffer system, and a linear elution method was used to collect the target protein. The final SEC-HPLC monomer purity reached more than 95%.

[0216] The schematic diagram of the structure of the prepared bispecific antibody molecule antibody 23 is shown in Figure 2a As shown, the schematic diagram of the structure of antibody 24 is shown Figure 2b As shown, the schematic diagram of the structure of antibody 27 is shown Figure 2c As shown, the schematic diagram of the structure of antibody 28 is as follows Figure 2d The amino acid sequence of the bispecific antibody molecule is shown in Table 1 below.

[0217] Table 1 Amino acid sequences contained in bispecific antibody molecules

[0218] Antibody 23 Antibody 24 Antibody 27 Antibody 28 First polypeptide chain SEQ ID NO: 13 SEQ ID NO: 13 SEQ ID NO: 13 SEQ ID NO: 17 Second polypeptide chain SEQ ID NO: 14 SEQ ID NO: 15 SEQ ID NO: 16 SEQ ID NO: 18

[0219] Example 2. Stability of bispecific antibodies

[0220] 1. Thermal stability of bispecific antibodies

[0221] DSF (differential scanning fluorescence) was used to investigate the stability of the bispecific antibody in a buffer system (20 mM histidine-histidine hydrochloride buffer, 230 mM sucrose, pH 5.0).

[0222] The bispecific antibody sample was replaced into the above buffer system, the sample concentration was controlled at about 10 mg / mL, and the nanoDSF was used for detection. The results are shown in Table 2. The thermal transition temperatures (Tm) of the bispecific antibodies 23, 24 and 27 provided in the present application were all above 56°C, showing good thermal stability.

[0223] Table 2 Thermal stability of bispecific antibodies

[0224] sample Tm1(℃) Tm2(℃) Tm3(℃) Antibody 23 59.1 / / Antibody 24 63.8 / / Antibody 27 56.2 66.5 76.6

[0225] Note: “ / ” means it does not exist

[0226] 2. Long-term stability of bispecific antibodies

[0227] The bispecific antibody samples were replaced in a pH 5.0 buffer system (20 mM histidine-histidine hydrochloride buffer, 230 mM sucrose), the concentration of the bispecific antibody samples was controlled at about 10 mg / mL, and the samples were dispensed into vials at 500 μL / tube and placed in a 5°C medical refrigerator to investigate the stability at 0, 2, and 4 weeks. The stability was evaluated by the following parameters: (a) SEC-HPLC (size exclusion high performance liquid chromatography) was used to measure the content of antibody monomers, polymers, and fragments; (b) CE-SDS (sodium dodecyl sulfate capillary electrophoresis) was used to detect the molecular weight of the antibody; (c) the isoelectric point of each component sample was detected using a capillary electrophoresis instrument (Maurice Instrument) equipped with an icIEF cartridge. After the sample was diluted with the iCIEF mixture, it was detected using a capillary electrophoresis instrument (Maurice). Components with different isoelectric points were focused at different positions to achieve the effect of focusing and separation; (d) ELISA and reporter gene methods were used to detect the biological activity of the antibody.

[0228] Wherein, (a) SEC-HPLC (size exclusion high performance liquid chromatography) for measuring the content of antibody monomers, polymers and fragments comprises the steps of: using a SEC column (Waters XBridge BEH, 7.8 mm×30 cm, 3.5 μm, ) was used to detect SEC purity by HPLC (Waters e2695 instrument). Each sample was diluted to 4.0 mg / mL with mobile phase, mixed and added to the inner liner tube, and directly injected for analysis; the mobile phase composition was 50 mM phosphate solution (containing 300 mM sodium chloride), pH 6.8±0.2. The relative percentages of the main peak, aggregates and fragments were calculated by area normalization method. The pretreatment method and test method of the reference sample were the same as those of the sample. The test parameters are shown in Table 3 below:

[0229] Table 3 SEC-HPLC purity test parameters

[0230]

[0231] (b) R-CE-SDS (reduced sodium dodecyl sulfate capillary electrophoresis) detection of the molecular weight of the antibody includes the following steps: rCE-SDS purity detection using a capillary electrophoresis instrument (Maurice instrument). Take a diluent (1wt% SDS + 40mM phosphate buffer, pH 6.5) to dilute each sample to 1 mg / mL, then take 95μL of the diluted sample and mix it with 5μL of 2-mercaptoethanol, centrifuge at 3000 rpm at room temperature for 30s, and then incubate at 70°C for 15 min. After the incubation is completed, cool to room temperature and centrifuge at 12000rpm at room temperature for 5 min. Take out 75μL of sample solution from the sample tube and put it into a 96-well plate to avoid bubbles, centrifuge at 1000g at room temperature for 10min, and detect it using a capillary electrophoresis instrument (Maurice). The pretreatment method and test method of the reference product are the same as the sample.

[0232] NR-CE-SDS (non-reduced sodium dodecyl sulfate capillary electrophoresis) detection of antibody molecular weight includes the following steps: nrCE-SDS purity detection using a capillary electrophoresis instrument (Maurice Instrument). Calculate the diluent and sample amount to be added when each sample is diluted to 1 mg / mL according to the final volume of 100 μL, and then add the diluent (1wt% SDS+40mM phosphate buffer, pH6.5), 5.0 μL 0.25M NEM (N-ethylmaleimide), and sample in the order of 1.5mL EP tube to mix. Centrifuge at 3000rpm for 30s at room temperature, then incubate at 70°C for 5min. After incubation, cool to room temperature and centrifuge at 12000rpm for 5min at room temperature. Take out 75μL of sample solution from each sample tube to a 96-well plate to avoid bubbles, centrifuge at 1000g for 10min at room temperature, and detect using a capillary electrophoresis instrument (Maurice Instrument). The pretreatment method and test method of the reference product are the same as those of the sample.

[0233] (c) The isoelectric point of each component sample was detected by using a capillary electrophoresis instrument (Maurice Instrument) equipped with an icIEF cartridge, and the focusing and separation effects were achieved by focusing components with different isoelectric points at different positions. The steps for detecting the isoelectric point include: diluting the sample (reference product / test product) to 1.0 mg / mL with ultrapure water, taking 20 μL of sample solution (1.0 mg / mL) and ultrapure water (blank sample) and mixing them with 80.0 μL of icIEF Master Mix, centrifuging at 10000 rpm for 5 min, taking 75.0 μL of the supernatant and adding it to a 96-well plate, paying attention to avoid bubbles, and then centrifuging the 96-well plate at 1000 g for 5 min to remove bubbles. The capillary electrophoresis instrument (Maurice Instrument) was used for detection. The pretreatment method and test method of the reference product were the same as those of the sample. The focusing and separation effects were achieved by focusing components with different isoelectric points at different positions. The preparation of the mixed solution icIEF Master Mix is ​​shown in Table 4 below, and the analysis method parameters are shown in Table 5.

[0234] Table 4 Preparation of icIEF Master Mix

[0235]

[0236] Table 5 Sample running method parameters

[0237]

[0238]

[0239] (d) ELISA method for detecting the biological activity of antibodies includes the following steps: using an indirect method, using human PD-1 (Human PD-1) and human VEGF (Human VEGF) as antigens to coat a 96-well plate, the antibody can bind to Human PD-1 and Human VEGF, Mouse Anti-Human IgG4 Fc-HRP (HRP-labeled mouse anti-human IgG4 (Fc) secondary antibody, manufacturer: SouthernBiotech; catalog number: 9200-05) can specifically bind to the antibody bound to the solid phase antigen (Human PD-1, Human VEGF, which can catalyze TMB (trimethyl borate) to develop a blue color under the action of hydrogen peroxide, and the depth of the blue color is positively correlated with the amount of Mouse Anti-HumanIgG4 Fc-HRP bound, and turns yellow after being terminated with 2M hydrochloric acid. The absorbance (OD value) is measured at a wavelength of 450nm / 620nm using an enzyme reader, and the effective binding activity (EC 50 ) to investigate the ability of the dual antibodies to bind to Human PD-1 and Human VEGF, respectively. See Tables 6 and 7 below for details:

[0240] Table 6 Antibody binding PD-1 ELISA experimental method

[0241]

[0242] Table 7 Antibody binding to VEGF ELISA experimental method

[0243]

[0244]

[0245] The reporter gene method for detecting the biological activity of antibodies includes the following steps:

[0246] (1) VEGF: Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a highly specific vascular endothelial cell growth factor that promotes vascular permeability, extracellular matrix degeneration, vascular endothelial cell migration, proliferation and angiogenesis. The high-affinity receptor that VEGF specifically binds to is called vascular endothelial growth factor receptor (VEGFR), which is mainly divided into three types: VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-1 and VEGFR-2 are mainly distributed on the surface of tumor vascular endothelium and regulate the formation of tumor blood vessels; VEGFR-3 is mainly distributed on the surface of lymphatic endothelium and regulates the formation of tumor lymphatic vessels. This application uses target cells 293VEGFR2 and recombinant VEGF (R&Dsystems, cat#11066-HNAB) proteins that overexpress VEGFR2 and luciferase reporter gene systems to detect the biological activity of antibody cells. Target cell 293VEGFR2 cells were inoculated into a 96-well flat-bottom white plate (corning, cat#3917) at 50,000 cells per well, and gradient dilutions of the antibody to be tested were added; then diluted working concentrations of 25ng / mL VEGF protein were added and incubated at 37°C for 5-6h. Finally, the luciferase substrate One-Lite (Vazyme, cat#DD1203-03-AB) was added and chemiluminescence was detected.

[0247] (2) PD-1 end: NFAT is a key transcription factor for downstream signaling of T cell receptor activation, and is essential for IL-2 secretion and T cell proliferation response. The antibody can specifically bind to PD-1 on the cell surface, blocking the PD-1 / PD-L1 interaction, thereby activating the downstream NFAT signaling pathway. The system of the present application includes two cell lines: Jurkat PD-1 effector cells (purchased from Promega), which stably express human PD-1 and luciferase reporter genes coupled to NFAT on Jurkat cells; CHO PDL1 target cell line (purchased from Promega), which stably expresses CD3scFv and human PDL1 on CHO-K1 cells. When PD-1 on the surface of the effector cell binds to PDL1 on the surface of the target cell, the NFAT signaling pathway is inhibited, and the expression of the luciferase reporter gene coupled thereto is inhibited. The antibody can specifically bind to PD-1, blocking the PD-1 / PDL1 interaction, thereby activating the downstream NFAT signaling pathway. The detection scheme of this application is: on the first day, the target cells PD-L1aAPC / CHO-K1 cells are plated and cultured in a cell culture incubator overnight; on the second day, the experimental antibody is prepared, and then the effector cells are added; 37°C, 5% (volume fraction) CO2 incubator is cultured for 4-6 hours; luciferase substrate is added, the multi-function microplate reader is used to read the plate and perform data analysis.

[0248] The test results showed that the purity (SEC-HPLC method, R-CE-SDS (reduction electrophoresis method), NR-CE-SDS (non-reduction electrophoresis method), icIEF) and biological activity of the three bispecific antibody molecules did not change significantly and had good long-term stability. The specific results are shown in Table 8.

[0249] Table 8 Stability of bispecific antibodies at 5°C for 4 weeks

[0250]

[0251] Note: “ / ” means not determined, “ND” means not measured

[0252] 3. Serum stability of bispecific antibodies

[0253] The bispecific antibody sample was replaced in a pH 5.0 buffer system (20mM histidine-histidine hydrochloride buffer, 230mM sucrose), the bispecific antibody sample concentration was controlled at about 10mg / mL, and then the sample was diluted to 1mg / mL with human serum, and dispensed into vials at 500μL / vial, placed in a 37°C incubator, and the stability was investigated at 0 weeks, 2 weeks, and 4 weeks. The biological activity of the antibody was detected by ELISA and reporter gene methods. The specific detection method is the same as the corresponding method in "2. Long-term stability of bispecific antibodies" above.

[0254] The test results showed that after being placed at 37°C for 4 weeks, the biological activities of the serum stability samples of Antibody 23, Antibody 24 and Antibody 27 did not change significantly, and they had good serum stability. The specific results are shown in Table 9.

[0255] Table 9 Bispecific Antibody Serum Stability Samples Stability at 37°C for 4 Weeks

[0256]

[0257] Note: “ / ” indicates not measured

[0258] Example 3. Determination of kinetic parameters of bispecific antibodies

[0259] 1. Determination of kinetic parameters of bispecific antibodies and antigen PD-1

[0260] The molecular interaction analyzer Octet RED96e (Sartorius) was used to capture 5 μg / mL JS001 (recombinant humanized anti-PD-1 monoclonal antibody reference product, prepared by Suzhou Junmeng Biomedical Technology Co., Ltd. according to the antibody sequence of the generic name Toripalimab, wherein the amino acid sequence of LC is shown in SEQ ID NO: 31, and the amino acid sequence of HC is shown in SEQ ID NO: 32), antibody 23, antibody 24, antibody 27, and antibody 28, respectively, and bound to 210nM and 70nM recombinant human PD-1 (prepared by Suzhou Junmeng Biomedical Technology Co., Ltd. according to the sequence of NCBI GenBank: NM_005018), and the binding and dissociation kinetic signals were detected. The analysis software Octet Data Analysis 12.0 was used to fit the binding and dissociation curves and calculate the affinity K D value.

[0261] Specific results such as Figure 3a-3e As shown in Table 10, Figure 3a This is the binding and dissociation curve diagram of antibody JS001 and human PD-1; Figure 3b It is the binding and dissociation curve diagram of antibody 23 and human PD-1; Figure 3c It is the binding and dissociation curve diagram of antibody 24 and human PD-1; Figure 3d It is the binding and dissociation curve diagram of antibody 27 and human PD-1; Figure 3e Figure 2 is the binding and dissociation curve of antibody 28 and human PD-1. Figure 3a-3e It can be seen from Table 10 that antibody JS001, antibody 23, antibody 24, antibody 27, and antibody 28 all have binding activity to human PD-1 with similar affinities; the above results indicate that bispecific antibody 23, antibody 24, antibody 27, and antibody 28 all maintain the affinity of their original anti-PD-1 monoclonal antibody JS001.

[0262] Table 10 Binding and dissociation data of JS001 and Antibody 23, Antibody 24, Antibody 27, Antibody 28 molecules with human PD-1

[0263]

[0264] 2. Determination of kinetic parameters of bispecific antibodies and VEGFA

[0265] The molecular interaction analyzer Octet RED96e was used to capture 5 μg / mL DotAb4 (the DotAb4 sequence was obtained from DotBio and expressed. The amino acid sequence of DotAb4 is shown in SEQ ID NO: 33, i.e.

[0266] The bold underlined part is the VHH sequence targeting VEGF), antibody 23, antibody 24, and antibody 27 were combined with 50nM and 25nM recombinant human VEGFA (purchased from Sino Biological, catalog number 11066-HNAB), respectively, to detect the binding and dissociation kinetic signals. The molecular interaction analyzer Octet was used to capture 5μg / mL antibody 28, and the binding and dissociation kinetic signals were detected by combining with 25nM and 12.5nM VEGFA. The analysis software Octet DataAnalysis 12.0 was used to fit the binding and dissociation curves and calculate the affinity K D value.

[0267] Specific results such as Figure 4a-4e As shown in Table 11, Figure 4a It is the binding and dissociation curve diagram of antibody DotAb4 and human VEGFA; Figure 4b is the binding and dissociation curve diagram of antibody 23 and human VEGFA; Figure 4c is the binding and dissociation curve diagram of antibody 24 and human VEGFA; Figure 4d is the binding and dissociation curve diagram of antibody 27 and human VEGFA; Figure 4e Figure 2 is the binding and dissociation curve of antibody 28 and human VEGFA. Figure 4a-4e As can be seen from Table 11, antibodies DotAb4, 23, 24, 27, and 28 all have strong binding activity to human VEGFA, and K D All are less than 0.5 nM; the above results indicate that bispecific antibodies 23, 24, 27, and 28 all maintain the affinity of their original anti-VEGFA nanoantibody DotAb4.

[0268] Table 11 Binding and dissociation data of DotAb4, Antibody 23, Antibody 24, Antibody 27, Antibody 28 and human VEGFA

[0269]

[0270] 3. Activity determination of bispecific antibodies binding to PD-1 and VEGFA simultaneously

[0271] The molecular interaction analyzer Biacore T200 (GE Healthcare Life Sciences) was used to detect the ability of bispecific antibody 27 to simultaneously bind to two target antigens, human PD-1 and human VEGFA. The test process includes: coupling 20μg / mL anti-mouse Fc fragment antibody to capture the PD-1 antigen with a mouse Fc tag. For the antibody 27 test sample group, that is, the detection of the ability of antibody 27 to simultaneously bind to PD-1 and VEGFA, first capture 2μg / mL PD-1, then inject 100nM antibody 27, and finally inject 80nM human VEGFA or buffer to detect the binding signal of human VEGA, that is, the signal of antibody 27 binding to VEGFA after binding to PD-1. At the same time, a negative control group was set up, first capture 2μg / mL PD-1, then inject buffer, and finally inject 80nM human VEGFA or buffer to detect the binding signal of human VEGFA to determine whether VEGFA will produce non-specific binding with PD-1. At the same time, another negative control group was set up. First, 2 μg / mL PD-1 was captured, then 100 nM anti-PD-1 monoclonal antibody JS001 was injected, and finally 80 nM human VEGFA or buffer was injected to detect the binding signal generated by human VEGFA to determine whether VEGFA generated non-specific binding signals with the anti-PD-1 antibody region.

[0272] Specific results such as Figure 5a-5c As shown in Table 12, Figure 5a This is the result graph of the test sample group antibody 27 binding to two antigens, human PD-1 and human VEGFA; Figure 5b This is the non-specific binding result diagram of human VEGFA and human PD-1 in the negative control group; Figure 5c This is the non-specific binding result of human VEGFA and JS001 in the negative control group. Figure 5a-5c As can be seen from Table 12: for the test sample group, the binding signal generated by VEGFA is 41.2RU, indicating that the bispecific antibody 27 can bind to both human PD-1 and human VEGFA antigens at the same time; the signal generated by VEGFA in the two negative control groups is only 1.0RU or 1.5RU, indicating that VEGFA will not produce non-specific binding with the antigen PD-1, nor will it produce non-specific binding with the Fab or Fc region of the anti-PD-1 antibody JS001.

[0273] Table 12 Simultaneous binding data of antibody 27 to human PD-1 and human VEGFA

[0274]

[0275] Example 4: ELISA method to detect the binding activity of bispecific antibodies and antigens

[0276] 1. ELISA method to detect the binding of bispecific antibodies to antigen PD-1

[0277] Use PBS (manufacturer: Hyclone, catalog number: SH30256.01) to dilute human PD-1 to 0.3 μg / mL, add 100 μL / well to the ELISA plate, and place it in a 37°C constant temperature incubator for coating for 90 minutes; wash the plate; add 200 μL / well 2% BSA (bovine serum albumin, 2% is 1 g BSA plus 50 mL PBS) to the plate, and incubate it in a 37°C constant temperature incubator for 90 minutes; wash the plate; dilute the sample to 1000 ng / mL with 2% BSA, and dilute it to 0.0419 ng / mL in a 2.5-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the horseradish peroxidase (HRP)-coupled mouse anti-human antibody IgG4 (manufacturer: Southern Biotech, catalog number: 9200-05) (Fc specific) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color developing solution TMB (trimethyl borate, manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL, 100 μL / well, avoiding bubbles, and coloring at 37°C in the dark for 15 min; finally, 2M hydrochloric acid solution was added to terminate the reaction, 100 μL / well, avoiding bubbles, and the ELISA reader reading was completed within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the EC was obtained by fitting using the four-parameter logarithmic regression (4PL) model. 50 (half maximal effect concentration).

[0278] Specific results such as Figure 6a , Figure 6b As shown in Table 13, Figure 6a ELISA curves of the binding of antibody 23 and antibody 24 to human PD-1; Figure 6b Figure 2 is the ELISA curve of the binding of antibody 27 and antibody 28 to human PD-1; TAB001 (JS001) is the control group. Figure 6a , Figure 6b As can be seen from Table 13, bispecific antibody 23, antibody 24, antibody 27, and antibody 28 all have good binding activity with human PD-1.

[0279] Table 13 Binding data of Antibody 23, Antibody 24, Antibody 27, Antibody 28 molecules to human PD-1

[0280] sample Antibody 23 Antibody 24 Antibody 27 Antibody 28 Relative binding activity (%) 52 25 77 31

[0281] Note: Take TAB001 (JS001) data as reference

[0282] 2. ELISA method to detect the binding of bispecific antibodies to antigen VEGFA

[0283] Use PBS (manufacturer: Hyclone, catalog number: SH30256.01) to dilute recombinant human VEGFA (manufacturer: SinoBiological, catalog number: 11066-HNAB) to 0.5 μg / mL, add 100 μL / well to the ELISA plate, and let it stand in a 37°C constant temperature incubator for coating for 90 minutes; wash the plate; add 200 μL / well 2% BSA to the plate, and incubate in a 37°C constant temperature incubator for 90 minutes; wash the plate; dilute the sample to 1000 ng / mL with 2% BSA, and dilute it to 0.0056 ng / mL in a 3-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the horseradish peroxidase (HRP)-coupled mouse anti-human antibody IgG4 (manufacturer: Southern Biotech, catalog number: 9200-05) (Fc specific) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color developing solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL, 100 μL / well, avoiding bubbles, and coloring at 37°C in the dark for 15 min; finally, 2M hydrochloric acid solution was added to terminate the reaction, 100 μL / well, avoiding bubbles, and the ELISA reader reading was completed within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the EC was obtained by fitting using the four-parameter logarithmic regression (4PL) model. 50 .

[0284] Specific results such as Figure 7a , Figure 7b As shown in Table 14, Figure 7a ELISA curves of the binding of antibody 23, antibody 24 and human VEGFA; Figure 7b The ELISA curves of antibody 27 and antibody 28 binding to human VEGFA; Avastin (bevacizumab, recombinant humanized anti-VEGF monoclonal antibody; manufacturer: Roche) was used as the control group. Figure 7a , Figure 7b As can be seen from Table 14, bispecific antibody 23, antibody 24, antibody 27, and antibody 28 all have good binding activity to human VEGFA.

[0285] Table 14 ELISA data of antibody 23, antibody 24, antibody 27, antibody 28 binding to human VEGFA

[0286] sample Antibody 23 Antibody 24 Antibody 27 Antibody 28 Relative binding activity (%) 175 27 53 57

[0287] Note: Avastin data is used as a control

[0288] 3. Competitive ELISA method to determine the activity of bispecific antibodies competing with VEGFR2 for binding to antigen VEGFA

[0289] Use PBS (manufacturer: Hyclone, catalog number: SH30256.01) to dilute recombinant human VEGFA (manufacturer: SinoBiological, catalog number: 11066-HNAB) to 0.5μg / mL, add 100μL / well to the ELISA plate, and place it in a 37℃ constant temperature incubator for coating for 90 minutes; wash the plate; add 200μL / well 2% BSA to the plate, and incubate it in a 37℃ constant temperature incubator for 90 minutes; wash the plate; dilute VEGFR2 His tag-biotinylated (manufacturer: Sino Biological, catalog number: 10012-H08H-B) to 0.3μg / mL with 2% BSA, and then dilute the sample to 100000ng / mL with 0.3μg / mL VEGFR2 His tag-biotinylated, and dilute it to 0.56ng / mL in a 3-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-coupled Streptavidin (manufacturer: Jackson ImmunoResearch, catalog number: 016-030-084) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color developing solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL, 100 μL / well, avoiding bubbles, and coloring at 37°C in the dark for 15 min; finally, 2M hydrochloric acid solution was added to terminate the reaction, 100 μL / well, avoiding bubbles, and the ELISA reader reading was completed within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the IC was obtained by fitting using the four-parameter logarithmic regression (4PL) model. 50 (half inhibitory concentration).

[0290] Specific results such as Figure 8a , Figure 8b As shown in Table 15, Figure 8a It is the competitive inhibition ELISA curve diagram of antibody 23 and antibody 24 blocking human VEGFR2 and VEGFA; Figure 8bThe figure is the competitive inhibition ELISA curve of antibody 27 and antibody 28 blocking human VEGFR2 and VEGFA; Avastin is the control group. Figure 8a , Figure 8b As can be seen from Table 15, bispecific antibody 23, antibody 24, antibody 27, and antibody 28 can all effectively block the binding between human VEGFR2 and human VEGFA.

[0291] Table 15 Competitive inhibition ELISA data of antibodies 23, 24, 27, 28 blocking human VEGFR2 and VEGFA

[0292] sample Antibody 23 Antibody 24 Antibody 27 Antibody 28 Relative binding activity (%) 97 61 85 163

[0293] Note: Avastin data is used as a control

[0294] 4. Competitive ELISA method to determine the activity of bispecific antibodies and PD-L1 in competing with the antigen PD-1

[0295] Use PBS (manufacturer: Hyclone, catalog number: SH30256.01) to dilute Human PD-1 (manufacturer: Suzhou Junmeng) to 1.5μg / mL, add 100μL / well to the ELISA plate, and place it in a 37℃ constant temperature incubator for coating for 90 minutes; wash the plate; add 200μL / well 2% BSA to the plate, and incubate it in a 37℃ constant temperature incubator for 90 minutes; wash the plate; dilute Biotin-PD-L1 hFc to 4.0μg / mL with 2% BSA. Then dilute the sample to 100000ng / mL with 4.0μg / mL Biotin-PD-L1 hFc, and dilute it to 0.56ng / mL in a 3-fold gradient. All samples were added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; horseradish peroxidase (HRP)-coupled Streptavidin (manufacturer: Jackson ImmunoResearch, catalog number: 016-030-084) was diluted 5000 times with 2% BSA and added to the ELISA plate at 100 μL / well and incubated in a 37°C constant temperature incubator for 60 min; the plate was washed; the color developing solution TMB (manufacturer: Sigma, catalog number: T2885) 0.1 mg / mL, 100 μL / well, avoiding bubbles, and coloring at 37°C in the dark for 15 min; finally, 2M hydrochloric acid solution was added to terminate the reaction, 100 μL / well, avoiding bubbles, and the ELISA reader reading was completed within 10 min (detection wavelength 450 nm; reference wavelength 620 nm), and the IC was obtained by fitting using the four-parameter logarithmic regression (4PL) model. 50 .

[0296] Specific results such as Figure 9a , Figure 9b As shown in Table 16, Figure 9a This is the competitive inhibition ELISA curve of antibody 23 and antibody 24 blocking human PD-L1 and PD-1; Figure 9b The figure is the competitive inhibition ELISA curve of antibody 27 and antibody 28 blocking human PD-L1 and PD-1; TAB001 (JS001) is the control group. Figure 9a , Figure 9b As can be seen from Table 16, bispecific antibody 23, antibody 24, antibody 27, and antibody 28 can all effectively block the binding of human PD-L1 to human PD-1.

[0297] Table 16 Competitive inhibition ELISA data of antibodies 23, 24, 27, and 28 blocking human PD-L1 and PD-1

[0298] sample Antibody 23 Antibody 24 Antibody 27 Antibody 28 Relative binding activity (%) 46 55 86 45

[0299] Note: Take TAB001 (JS001) data as reference

[0300] Example 5. Cellular Function Activity of Bispecific Antibodies

[0301] 1. Activity detection of bispecific antibodies in PD-1 / PD-L1 luciferase reporter gene system

[0302] Target CHO PD-L1 cells (human PD-L1 and CD3 scFv stably expressed on CHO cells, purchased from Promega) were plated in a 96-well white flat-bottom plate at a rate of 5 × 10 4 The cells were plated overnight; the next day, the medium in the cell wells was aspirated, and different concentrations of bispecific antibodies or control antibodies (starting concentration was 500nM, 4-fold dilution, a total of 9 concentration gradients) were added to the target cells with experimental buffer (RPMI 1640 medium (1×) + 1% FBS (fetal bovine serum)) and incubated at 37°C for 30 minutes. Then, effector cells Jurkat PD-1 (stable expression of human PD-1 and luc2P / NFAT-RE on Jurkat cells, purchased from Promega) were added at 1×10 per well. 5 The cells were added to the cell plate and incubated in a 37°C incubator for 6 hours; finally, ONE-Lite luciferase detection reagent (Vazyme, Cat#1203-03) was added to the cell antibody mixture system, and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000 pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the EC 50 The positive control was JS001 (recombinant humanized anti-PD-1 monoclonal antibody).

[0303] The results are as follows Fig.10aand Fig.10b As shown, Fig.10a This is a graph showing the activity test results of antibody 23 and antibody 24 in the PD-1 / PD-L1 luciferase reporter gene system; Fig.10b The figure shows the activity test results of antibody 27 and antibody 28 in the PD-1 / PD-L1 luciferase reporter gene system. Fig.10a and Fig.10b It can be seen that antibody 23 (IgG4), antibody 24 (IgG4), antibody 27 (IgG4), antibody 28 (IgG4) and JS001 can effectively activate the activity of T cells in the above reporter gene system. 50 The activity of antibody 23 and antibody 24 were better than JS001, and the activity of antibody 27 was comparable to that of JS001.

[0304] 2. Activity detection in luciferase reporter gene system of bispecific antibody blocking VEGF-induced NFAT signaling

[0305] The target cells 293VEGFR2 (stable expression of VEGFR2 (KDR) and NFAT-RE-luc 2p, purchased from China Food and Drug Inspection Institute) were plated in a 96-well white flat-bottom plate at 1×10 per well. 5 The number of cells was plated; different concentrations of bispecific antibodies or control antibodies (starting concentration of 66.7nM, 3-fold dilution, a total of 10 concentration gradients) were added to the target cells using experimental buffer (DMEM medium + 2% FBS). Then VEGF antigen (Sino Biological, Cat#11066-HNAB, working concentration of 30ng / mL) was added to the cell plate and incubated in a 37°C incubator for 5 hours; finally, ONE-Lite luciferase detection reagent (Vazyme, Cat#1203-03) was added to the cell-antibody mixture system, and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000 pro). The four-parameter regression curve was fitted by GraphPad prism software to calculate the IC 50 The positive control was Avastin (chemical name "bevacizumab", a recombinant humanized anti-VEGF monoclonal antibody).

[0306] The results are as follows Fig.11a and Fig.11b As shown, Fig.11a The figure shows the activity detection results of the luciferase reporter gene system in which antibodies 23 and 24 blocked VEGF-induced NFAT signaling; Fig.11bThe figure shows the activity detection results of the luciferase reporter gene system in which antibodies 27 and 28 blocked VEGF-induced NFAT signaling. Fig.11a and Fig.11b It can be seen that antibody 23, antibody 24, antibody 27, and antibody 28 can all specifically bind to the VEGF antigen, thereby blocking the binding of VEGF protein to its receptor, and then blocking the downstream signaling pathway, inhibiting tumor-induced angiogenesis, and the activities of antibody 24 and antibody 28 are comparable to Avastin, and the activity of antibody 23 is better than Avastin.

[0307] 3. Experiment on the inhibition of VEGFA-induced HUVEC cell proliferation by bispecific antibodies

[0308] VEGF antigen (working concentration of 10 ng / mL) was plated in a 96-well white plate; different concentrations of bispecific antibody or control antibody (the starting concentration of the bispecific antibody was 10 nM, 3-fold dilution, a total of 10 concentration gradients; the starting concentration of the control antibody was 66.7 nM, 3-fold dilution, a total of 10 concentration gradients) were added to the 96-well white plate using culture medium and the antibody and antigen were co-incubated in a 37°C incubator for 0.5 hours. HUVEC cells (purchased from Shanghai Aoneng Biotechnology Co., Ltd.) were then incubated at 3×10 3 The cells were plated in 96-well white plates and incubated in a 37°C incubator for 96 hours. Finally, Cell counting-Lite luciferase detection reagent (Vazyme, cat#DD1101-03) was added to the cell antibody antigen mixed system, and the chemiluminescent signal was detected using a multifunctional microplate reader (TECAN M1000 pro). The four-parameter regression curve was fitted using GraphPad prism software to calculate the IC 50 The positive control was Avastin.

[0309] The results are as follows Fig.12a and Figure 12b As shown, Fig.12a The figure shows the experimental results of antibody 23 and antibody 24 inhibiting VEGFA-induced HUVEC cell proliferation; Figure 12b The figure shows the experimental results of antibody 27 and antibody 28 inhibiting VEGFA-induced HUVEC cell proliferation. Fig.12a and Figure 12b It can be seen that antibody 23, antibody 24, antibody 27, and antibody 28 can all specifically bind to the VEGF antigen, thereby inhibiting the proliferation of HUVEC cells, and the activities of antibody 23, antibody 24, and antibody 28 are comparable to Avastin.

[0310] 4. Bispecific antibodies promote the secretion of cytokines IFN-γ and IL-2 in mixed lymphocyte reactions

[0311] Commercial human PBMC (purchased from Shanghai Aoneng Biotechnology Co., Ltd.) were purified using CD14 MicroBeads, Human (Miltenyi Biotec, cat#130-050-201) to obtain CD14 cells. The adherent cells were then stimulated with 10 ng / mL GM-CSF (Sino Biological, cat# GMP-11846-HNAE) and 10 ng / mL IL-4 (Sino Biological, cat# GMP-10015-HNAH) for 5 days, and then stimulated with 5 ng / mL IL-1β (Sino Biological, cat# 10139-HNAE), 10 ng / mL IL-6 (Sino Biological, cat# GMP-10395-HNAE), 10 ng / mL TNF-α (Sino Biological, cat# GMP-10602-HNAE) and 1 μmol / L PGE2 (Dinoprostone) for 2 days to induce mature dendritic cells (mDC, donor 1). CD4 T cells (donor 2) were obtained by purifying commercial human PBMCs using CD4T MicroBeads, Human (Miltenyi Biotec, cat#130-045-101).

[0312] In a 96-well round-bottom plate, different concentrations of the test antibody (starting concentration of 150 nM, 10-fold dilution, a total of 4 concentration gradients) and mDC cells (10,000 cells per well) and the above-purified CD4 T cells (100,000 cells per well) were co-incubated in a CO2 incubator at 37°C for 5 days. On the third day of co-incubation, part of the reaction supernatant was collected from each well of the 96-well plate and IL-2 release was detected using BDCBA human IL2 Flex set (BD, cat#558270), and the IFNγ content in the supernatant was detected using BD CBAhuman IFNγFlex set (BD, cat#558269) on the fifth day of co-incubation. The positive control was the antibody Ref1 (ivonescimab, a recombinant humanized anti-PD-1 and VEGF bispecific antibody of Kangfang Bio; AK112, synthesized according to the INN public sequence (INN Number: 11809)).

[0313] The results are as follows Figure 13a-13d As shown, Fig.13a The figure is the experimental result that the antibody promotes the secretion of cytokine IL2 in the mixed lymphocyte reaction of donor 1; Fig.13bThe figure is the experimental result that the antibody promotes the secretion of cytokine IL2 in the mixed lymphocyte reaction of donor 2; Fig.13c The figure is the experimental result that the antibody promotes the secretion of cytokine IFNγ in the mixed lymphocyte reaction of donor 1; Fig.13d The figure shows the experimental results of the antibody promoting the secretion of cytokine IFNγ in the mixed lymphocyte reaction of donor 2. Figure 13a-13d It can be seen that in the mixed lymphocyte reaction, antibodies 23, 24, 27, 28 and the positive control group antibody Ref1 can all promote the release of IL-2 and IFNγ.

[0314] Example 6. In vivo efficacy of bispecific antibodies

[0315] The inhibitory effects of antibodies 23 and 27 of the present application on the B-hPD-1 mouse transplanted MC38 model.

[0316] Female B-hPD-1 humanized mice aged 6-8 weeks (purchased from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.) were inoculated subcutaneously on the right side with 1×10 6 MC38 cells (purchased from Nanjing Kebai Biotechnology Co., Ltd.). The average tumor volume was about 116 mm 3 When the tumor volume was quantified, appropriate animals were selected and randomly divided into 5 groups according to the tumor volume, with 6 animals in each group. They were: G1 saline control group (solvent control group); G2 JS001 (1 mg / kg) group; G3 DotAb4 (0.56 mg / kg) group; G4 antibody 23 (1.25 mg / kg) group and G5 antibody 27 (1.25 mg / kg) group.

[0317] Intraperitoneal injection, once every other day, for 9 consecutive times, the experiment was terminated 2 days after the last administration. Tumor volume and body weight were measured twice a week, and the weight and tumor volume of the mice were recorded. At the end of the experiment, the mice were euthanized, and the tumor inhibition rate TGI (%) was calculated, TGI (%) = [1-(Ti-T0) / (Vi-V0)] × 100% (Ti: the mean tumor volume of the treatment group on the i-th day of administration, T0: the mean tumor volume of the treatment group on the 0th day of administration; Vi: the mean tumor volume of the solvent control group on the i-th day of administration, V0: the mean tumor volume of the solvent control group on the 0th day of administration).

[0318] The results are shown in Table 17 and Fig.14 As shown, Fig.14 Table 17 is a graph showing the inhibitory effect of the test substance on the B-PD-1 humanized mouse transplanted MC38 tumor model, and Table 18 is a table showing the efficacy analysis of each group in the B-PD-1 humanized mouse transplanted MC38 tumor model (18 days after the start of administration). Fig.14It can be seen that on the 18th day after administration, the average tumor volume of the saline control group was 1815mm 3 The average tumor volume of the JS001 (1 mg / kg) group was 702 mm 3 Compared with the saline control group, the tumor inhibition rate was 65.5%, which significantly inhibited tumor growth; the average tumor volume of the DotAb4 (0.56 mg / kg) group was 968 mm 3 Compared with the saline control group, the tumor inhibition rate was 49.9%, showing a slight tumor inhibition effect. The average tumor volume of the antibody 23 (1.25 mg / kg) and antibody 27 (1.25 mg / kg) groups was 687 mm 3 and 505mm 3 Compared with the saline control group, the tumor inhibition rates were 66.4% and 77.1%, respectively, significantly inhibiting tumor growth.

[0319] Table 17 Efficacy analysis of each group in the B-PD-1 humanized mouse transplanted MC38 tumor model

[0320]

[0321]

[0322] Note: 1. Data are expressed as "mean ± standard error", "-" means not present;

[0323] 2.TGI%=[1-(Ti-T0) / (Vi-V0)]×100%;

[0324] 3. The P value was obtained by comparing the tumor volumes of each group using the T test method.

[0325] Example 7. Pharmacokinetics of bispecific antibodies in cynomolgus monkeys

[0326] Female cynomolgus monkeys (animal source: Guangxi Fangchenggang Changchun Biotechnology Development Co., Ltd.; license number: SCXK Gui 2018-0005) were given a single intravenous infusion of bispecific antibodies with different codes for 5 minutes, namely antibody Ref1 (ivonescimab, Kangfang Bio's recombinant humanized anti-PD-1 and VEGF bispecific antibody, AK112), antibody 23, and antibody 27, with a dose of 3 mg / kg, two per group, and about 1 mL of whole blood samples were collected at 0 minutes (before administration), 5 minutes (end of infusion), 1 hour, 6 hours, 24 hours, 48 ​​hours, 72 hours, 144 hours, 168 hours, 240 hours, 336 hours, and 504 hours. After the whole blood samples coagulated naturally, the serum was separated and stored for blood drug concentration detection.

[0327] The drug concentrations and metabolic kinetic parameters in the serum of each group of animals are summarized in Tables 18 and 19. (0-t) It refers to the area enclosed by the blood drug concentration curve on the time axis; t 1 / 2z Refers to the end-point blood drug concentration and its half-life; T max It refers to the peak time, the time required to reach the peak concentration of the drug after administration; Vz refers to the apparent distribution volume, the proportional constant between the amount of drug in the body and the blood concentration when the drug reaches dynamic equilibrium in the body; Clz refers to the clearance rate; C max It refers to the peak drug concentration, the highest blood drug concentration after administration.

[0328] Table 18 Summary of drug concentrations in serum of each group

[0329]

[0330]

[0331] Table 19 Pharmacokinetic parameters of each group

[0332]

[0333] As can be seen from Table 19, after a single intravenous infusion of the test drug at a dose of 3 mg / kg in female cynomolgus monkeys, the AUC(0-t) of antibody 27, antibody 23 and antibody ref1 (Kangfang) were 152.7±95.2, 141.7±37.0 and 113.5±25.1 μg / mL*d, respectively, indicating that a higher exposure level can be achieved after administration. The half-life t 1 / 2z The elimination efficiencies were 0.9±0.3, 1.0±0.2, and 1.6±0.2 days, respectively, which were comparable to those of conventional dual antibodies, indicating that the drug had good drugability. The Vz of antibody 27 and antibody 23 was 30-40 mL / kg, indicating that the drug was mainly in the circulation after intravenous injection in monkeys, without extravascular distribution.

[0334] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.

Claims

1. A bispecific antibody comprising a first protein functional region and a second protein functional region; wherein: The first protein functional region is an anti-PD-1 antibody or an antigen-binding fragment thereof, the second protein functional region is an anti-VEGF antibody or an antigen-binding fragment thereof, the anti-VEGF antibody or the antigen-binding fragment thereof comprises a heavy chain variable region, and the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively.

2. The bispecific antibody according to claim 1, wherein The anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region; the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region are respectively selected from the amino acid sequences of HCDR1, HCDR2 and HCDR3 contained in the heavy chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab; the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region are respectively selected from the amino acid sequences of LCDR1, LCDR2 and LCDR3 contained in the light chain variable region of nivolumab, pembrolizumab, cemiprilimumab, toripalimab, sintilimab or carrelizumab.

3. The bispecific antibody according to claim 1 or 2, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and / or a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 having amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3 having amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

4. The bispecific antibody according to any one of claims 1 to 3, wherein The anti-PD-1 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 10, and a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 11; and / or The anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO:

12.

5. The bispecific antibody according to any one of claims 1 to 3, wherein The anti-PD-1 antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody; and / or The anti-VEGF antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single domain antibody, single chain antibody, humanized antibody, chimeric antibody or diabody.

6. The bispecific antibody according to any one of claims 1 to 5, wherein The first protein functional region is an immunoglobulin, and / or The second protein functional region is a single domain antibody.

7. The bispecific antibody according to claim 6, wherein The immunoglobulin is selected from IgG, IgA, IgD, IgE or IgM; preferably IgG.

8. The bispecific antibody according to claim 6, wherein The constant region of the immunoglobulin is derived from a human antibody; Preferably, the constant region of the immunoglobulin is selected from the constant region of human IgG1, IgG2, IgG3 or IgG4.

9. The bispecific antibody according to claim 6, wherein There are two single-domain antibodies, and one end of each single-domain antibody is connected to the C-terminus or N-terminus of the two heavy chains of the immunoglobulin respectively; or One end of each of the single-domain antibodies is connected to the C-terminus or N-terminus of the two light chains of the immunoglobulin; or The N-terminus of each single-domain antibody is respectively connected to the C-terminus of the heavy chain constant region CH1 of the immunoglobulin, and the C-terminus of each single-domain antibody is respectively connected to the N-terminus of the heavy chain constant region CH2 of the immunoglobulin.

10. The bispecific antibody according to claim 9, wherein (1) The first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHVEGF-linker-VHPD-1-CH1-hinge-CH2-CH3; or (2) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3-linker-VHVEGF; or (3) the first polypeptide chain of the bispecific antibody is represented by the formula VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-linker-VHVEGF-linker-hinge-CH2-CH3; or (4) The first polypeptide chain of the bispecific antibody is represented by the formula VHVEGF-linker-VLPD-1-CL, and the second polypeptide chain is represented by the formula VHPD-1-CH1-hinge-CH2-CH3.

11. The bispecific antibody according to claim 10, wherein (1) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 14; or (2) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 15; or (3) the first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 13, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 16; or (4) The first polypeptide chain comprises the amino acid sequence shown in SEQ ID NO: 17, and the second polypeptide chain comprises the amino acid sequence shown in SEQ ID NO:

18.

12. An isolated nucleic acid molecule encoding the bispecific antibody of any one of claims 1 to 11.

13. A vector comprising the isolated nucleic acid molecule of claim 12.

14. A host cell comprising the isolated nucleic acid molecule of claim 12, or the vector of claim 13. 15 . A method for preparing the bispecific antibody according to claim 1 , comprising the steps of culturing the host cell according to claim 14 , and obtaining the bispecific antibody from the culture.

16. A conjugate comprising the bispecific antibody according to any one of claims 1 to 11 and a conjugated moiety, wherein: The coupling moiety is a detectable label; preferably, the coupling moiety is selected from a radioisotope, a fluorescent substance, a luminescent substance, a colored substance or an enzyme.

17. A kit comprising the bispecific antibody according to any one of claims 1 to 11, or the conjugate according to claim 16; Preferably, the kit further comprises a second antibody, which is capable of specifically binding to the bispecific antibody; preferably, the second antibody further comprises a detectable label, and more preferably, the detectable label is selected from a radioactive isotope, a fluorescent substance, a colored substance or an enzyme.

18. Use of the bispecific antibody according to any one of claims 1 to 11 in preparing a kit; preferably, the kit is used to detect the presence or level of VEGF and / or PD-1 in a sample.

19. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 1 to 11 or the conjugate according to claim 16; preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

20. Use of the bispecific antibody according to any one of claims 1 to 11, the conjugate according to claim 16, or the pharmaceutical composition according to claim 19 in the preparation of a medicament for preventing and / or treating malignant tumors.

21. Use of the bispecific antibody according to any one of claims 1 to 11, the conjugate according to claim 16, or the pharmaceutical composition according to claim 19 in the preparation of the following drugs or reagents: A reagent for detecting the level of VEGF in a sample.

22. An in vitro method for non-diagnostic and non-therapeutic purposes, comprising the step of applying an effective amount of the bispecific antibody of any one of claims 1 to 11, the conjugate of claim 16, or the pharmaceutical composition of claim 19 to cells, the method being selected from the following: (1) A method for detecting the level of VEGF in a sample, or Methods of blocking the binding of VEGF to VEGFR, or A method for downregulating the activity or level of VEGF, or A method for relieving the stimulatory effect of VEGF on the proliferation of vascular endothelial cells, or A method for inhibiting the proliferation of vascular endothelial cells, or Methods to block tumor angiogenesis; and / or (2) Methods to block the binding of PD-1 to PD-L1, or A method for downregulating the activity or level of PD-1, or Methods to relieve the immune suppression of PD-1, or A method for promoting IFN-r secretion in T lymphocytes, or Methods for promoting IL-2 secretion in T lymphocytes.

Citation Information

Cited By

  • Process for affinity separation of active components in inonotus obliquus by using VEGFR2 (vascular endothelial growth factor receptor 2) extracellular domain and application

    CN121270642A

  • Anti-PD-1-Anti-VEGF bispecific antibody, pharmaceutical composition thereof and use thereof

    EP4717714A1

  • Anti-PD-1-Anti-VEGF bispecific antibody, pharmaceutical composition thereof and use thereof

    WO2024240171A1

  • Pharmaceutical composition comprising Anti-PD-1 / VEGF bispecific antibody and use thereof

    WO2026214643A1